229 related articles for article (PubMed ID: 36880209)
1. Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
Kim KA; Lee S; Park HJ; Jang ES; Lee YJ; Cho SB; Kim YS; Kim IH; Lee BS; Chung WJ; Ahn SH; Kim S; Jeong SH
Clin Mol Hepatol; 2023 Apr; 29(2):496-509. PubMed ID: 36880209
[TBL] [Abstract][Full Text] [Related]
2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
4. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Di Maio VC; Cento V; Lenci I; Aragri M; Rossi P; Barbaliscia S; Melis M; Verucchi G; Magni CF; Teti E; Bertoli A; Antonucci F; Bellocchi MC; Micheli V; Masetti C; Landonio S; Francioso S; Santopaolo F; Pellicelli AM; Calvaruso V; Gianserra L; Siciliano M; Romagnoli D; Cozzolongo R; Grieco A; Vecchiet J; Morisco F; Merli M; Brancaccio G; Di Biagio A; Loggi E; Mastroianni CM; Pace Palitti V; Tarquini P; Puoti M; Taliani G; Sarmati L; Picciotto A; Vullo V; Caporaso N; Paoloni M; Pasquazzi C; Rizzardini G; Parruti G; Craxì A; Babudieri S; Andreoni M; Angelico M; Perno CF; Ceccherini-Silberstein F;
Liver Int; 2017 Apr; 37(4):514-528. PubMed ID: 28105744
[TBL] [Abstract][Full Text] [Related]
5. Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life.
Ren S; Wei F; Jin Y; Lu J; He Z; Ma L; Zheng Y; Wang J; Chen X
Antivir Ther; 2020; 25(5):245-255. PubMed ID: 32936785
[TBL] [Abstract][Full Text] [Related]
6. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
[TBL] [Abstract][Full Text] [Related]
7. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
Di Maio VC; Barbaliscia S; Teti E; Fiorentino G; Milana M; Paolucci S; Pollicino T; Morsica G; Starace M; Bruzzone B; Gennari W; Micheli V; Yu La Rosa K; Foroghi L; Calvaruso V; Lenci I; Polilli E; Babudieri S; Aghemo A; Raimondo G; Sarmati L; Coppola N; Pasquazzi C; Baldanti F; Parruti G; Perno CF; Angelico M; Craxì A; Andreoni M; Ceccherini-Silberstein F;
Liver Int; 2021 Aug; 41(8):1802-1814. PubMed ID: 33497016
[TBL] [Abstract][Full Text] [Related]
8. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
Sarrazin C; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Pang PS; Chuang SM; Ma J; Ding X; Afdhal NH; Kowdley KV; Gane EJ; Lawitz E; Brainard DM; McHutchison JG; Miller MD; Mo H
Gastroenterology; 2016 Sep; 151(3):501-512.e1. PubMed ID: 27296509
[TBL] [Abstract][Full Text] [Related]
10. Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Soñora M; Cristina J; Moratorio G; Hernández N; Moreno P
BMC Infect Dis; 2021 Apr; 21(1):387. PubMed ID: 33902462
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C
Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790
[TBL] [Abstract][Full Text] [Related]
12. Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.
Milazzo L; Magni C; Niero F; Schiavini M; Lai A; Cento V; Binda F; Antinori S; Sollima S
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1231-1234. PubMed ID: 28877086
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
Sølund C; Pedersen MS; Fahnøe U; Filskov J; Jenssen H; Weis N; Schønning K; Bukh J
APMIS; 2023 Aug; 131(8):426-433. PubMed ID: 37355962
[TBL] [Abstract][Full Text] [Related]
14. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
Fahnøe U; Pedersen MS; Sølund C; Ernst A; Krarup HB; Røge BT; Christensen PB; Laursen AL; Gerstoft J; Thielsen P; Madsen LG; Pedersen AG; Schønning K; Weis N; Bukh J
J Viral Hepat; 2021 Feb; 28(2):302-316. PubMed ID: 33131178
[TBL] [Abstract][Full Text] [Related]
15. Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C.
Itakura J; Kurosaki M; Kakizaki S; Amano K; Nakayama N; Inoue J; Endo T; Marusawa H; Hasebe C; Joko K; Wada S; Akahane T; Koushima Y; Ogawa C; Kanto T; Mizokami M; Izumi N
JHEP Rep; 2020 Oct; 2(5):100138. PubMed ID: 32817930
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
[TBL] [Abstract][Full Text] [Related]
17. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
Wang GP; Schnell GL; Kort JJ; Sidhu GS; Schuster L; Tripathi RL; Larsen L; Michael LC; Bergquist K; Magee A; Patel CB; Whitlock JA; Tamashiro R; Peter JA; Fried MW; Nelson DR
J Hepatol; 2021 Oct; 75(4):820-828. PubMed ID: 34023351
[TBL] [Abstract][Full Text] [Related]
18. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.
Wyles D; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Martin R; Afdhal NH; Kowdley KV; Lawitz E; Brainard DM; Miller MD; Mo H; Gane EJ
J Hepatol; 2017 Apr; 66(4):703-710. PubMed ID: 27923693
[TBL] [Abstract][Full Text] [Related]
19. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
Uemura H; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Sugawara K; Nakao M; Motoya D; Nakayama N; Imai Y; Tomiya T; Mochida S
J Gastroenterol; 2019 May; 54(5):459-470. PubMed ID: 30612205
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection.
Huang W; Wang M; Gong Q; Yu D; Chen P; Lin J; Han Y; Su Y; Qu L; Zhang X
Microb Drug Resist; 2019; 25(6):944-950. PubMed ID: 30702389
[No Abstract] [Full Text] [Related]
[Next] [New Search]
